Table 1.
Baseline and waitlist characteristics of study population.
| Patients (N = 285) | |
|---|---|
| Median age at listing (years, IQR) | 67.0 (63.0–71.0) |
| Sex (n, %) | |
| Men | 214 (75.1) |
| Women | 71 (24.9) |
| Race (n, %) | |
| White | 127 (44.6) |
| Hispanic | 67 (23.5) |
| Asian/Pacific Islander | 60 (21.1) |
| African American | 13 (4.6) |
| Other | 18 (6.3) |
| Etiology of liver disease (n, %) | |
| Hepatitis B or C | 184 (64.6) |
| NASH | 44 (15.4) |
| Alcohol Use | 35 (12.3) |
| Other | 22 (7.7) |
| Tumor stage at diagnosis (n, %) | |
| Milan criteria | 239 (83.9) |
| UNOS downstaging | 32 (11.2) |
| All-comers | 14 (4.9) |
| Median number of HCC viable lesions on explant (n, IQR) | 1.0 (0–2.0) |
| Median size of largest tumor on explant (cm, IQR) | 1.0 (0–1.8) |
| Median total viable tumor on explant (cm, IQR) | 1.2 (0–3.0) |
| Locoregional therapy | |
| Ever received (n, %) | 270 (94.7) |
| Median number of treatments (n, IQR) | 2 (1–3) |
| Types of locoregional therapy (n, %) | |
| TACE | 189 (66.3) |
| RFA | 100 (35.1) |
| Y90 | 73 (25.6) |
| Median MELD at listing (n, IQR) | 11.0 (8.0–13.0) |
| Median MELD at transplant (n, IQR) | 17.0 (13.0–21.0) |
| Median waitlist time to LT (years, IQR) | 1.0 (0.6–1.4) |
| Median AFP at LT (ng/ml, IQR) | 5.0 (3.0–12.1) |
| AFP ≥100 ng/ml at LT (n, %) | 12 (4.2) |
| Median AFP-L3 at LT (%, IQR) | 6.7 (0.5–13.2) |
| AFP-L3 ≥15% at LT (n, %) | 57 (20.0) |
| Median DCP at LT (ng/ml, IQR) | 1.0 (0.3–2.8) |
| DCP ≥7.5 ng/ml at LT (n, %) | 40 (14.0) |
AFP, alpha-fetoprotein; AFP-L3, AFP bound to Lens culinaris agglutinin; DCP, des-gamma-carboxyprothrombin; HCC, hepatocellular carcinoma; LT, liver transplant; MELD, model for end-stage liver disease; NASH, non-alcoholic steatohepatitis; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; UNOS, United Network for Organ Sharing.